GLPwatch

Remitting Seronegative Symmetrical Synovitis with Pitting Edema Syndrome Worsen after the Administration of Dulaglutide.

Medicina (Kaunas) · 2022

Last updated 2026-05-28

A 91-year-old woman with RS3PE syndrome—marked by joint pain and swelling in the limbs—improved after treatment with prednisolone. However, her symptoms worsened after starting dulaglutide, a GLP-1 drug, with increased inflammation in her blood tests. Stopping dulaglutide led to improvement in both her symptoms and lab results.

AI summary of the abstract below.

JournalMedicina (Kaunas), 2022
Citations1
Relative citation ratio0.24
NIH percentile15
Molecules dulaglutide

Abstract

Remitting seronegative symmetrical synovitis with pitting edema (RS3PE) syndrome is characterized by symmetrical polyarthritis and limb pitting edema. Although the detailed mechanisms of this syndrome have not been clearly understood, some agents including dipeptidyl peptidase-4 inhibitors have been reported to induce RS3PE syndrome. However, glucagon-like peptide-1 (GLP-1) analogues have not been reported to be associated with this syndrome. A 91-year-old woman was admitted to our hospital with complaints of severe polyarthritis and limb edema. She was diagnosed with RS3PE syndrome. Oral prednisolone improved her symptoms. However, her symptoms worsened after the administration of dulaglutide, with elevated serum inflammatory markers. Discontinuation of dulaglutide without additional treatment improved her symptoms and laboratory findings. This case might indicate the possibility of development and worsening of RS3PE syndrome caused after GLP-1 analogue.

Verbatim abstract via PubMed 35208612 ↗

Related research